SBH
PRCT icon

Segall Bryant & Hamill’s Procept Biorobotics PRCT Stock Holding History

Segall Bryant & Hamill’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.77M Buy
211,301
+3,695
+2% +$92.5K 0.06% 325
2026
Q1 		$5.19M Sell
207,606
-10,737
-5% -$303K 0.07% 300
2025
Q4 		$6.87M Buy
218,343
+9,804
+5% +$325K 0.09% 276
2025
Q3 		$7.44M Buy
208,539
+5,098
+3% +$233K 0.1% 273
2025
Q2 		$11.7M Buy
203,441
+34,559
+20% +$1.95M 0.16% 202
2025
Q1 		$9.84M Buy
168,882
+26,843
+19% +$1.83M 0.15% 219
2024
Q4 		$11.4M Buy
142,039
+41,238
+41% +$3.52M 0.16% 202
2024
Q3 		$8.08M Buy
+100,801
New +$7.16M 0.11% 262

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Segall Bryant & Hamill's PRCT Position: Q2 2026 in Review

Segall Bryant & Hamill increased its Procept Biorobotics (PRCT) stake by 1.8% in Q2 2026, buying an estimated $92.5K and bringing the position to 211,301 shares worth $4.77M. The position accounts for 0.06% of the portfolio, ranked #325.

Segall Bryant & Hamill first reported a position in PRCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $11.7M in Q2 2025. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Segall Bryant & Hamill held 211,301 shares of Procept Biorobotics worth $4.77M as of Q2 2026.
  • Segall Bryant & Hamill bought 3,695 Procept Biorobotics shares in Q2 2026, an estimated $92.5K.
  • Procept Biorobotics made up 0.06% of Segall Bryant & Hamill's portfolio in Q2 2026, its #325 holding.
  • Segall Bryant & Hamill first reported a position in Procept Biorobotics in Q3 2024 and has held it in 8 quarters since.
  • Segall Bryant & Hamill's Procept Biorobotics position peaked at $11.7M in Q2 2025.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Segall Bryant & Hamill's 13F filing for Q2 2026, filed 12 Aug 2026.